Stay updated with breaking news from Usher Type. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) Tuesday announced its decision to acquire Akouos, Inc. (AKUS), a developer of viral gene therapies for the treatment of inner ear conditions
Sensorion: A Chardan Top Pick for 2021 Regulatory News: Sensorion (FR0012596468 ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the US healthcare investment bank Chardan decision to make Sensorion one of its top picks for 2021, calling the company "2021's hidden gem in gene therapy". It raised its target price to €7, following the announcement of a third gene therapy collaboration with Pasteur Institut targeting important pediatri...
(2) Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the company's Board of Directors has approved the procedure for holding an Extraordinary General Meeting behind closed doors ( à huis clos) on Wednesday, March 24, 2021. In accordance with article 4 of ordinance n° 2020-321 of March 25, 2020 as amended by ordinance n° 2020-1497 of December 2, 2020 adapting the rules for meetings and deliberations ...
(2) Key new findings by the Institut Pasteur concerning the gene target GJB2, enables Sensorion to potentially address important hearing loss segments in adults and children GJB2 mutations are the most prevalent cause of congenital deafness; the gene target potentially opens up a pipeline of indications Three initial indications to be targeted: congenital deafness, a progressive form of hearing loss in childhood and early onset of severe presbycusis in adults Webcast planned for Tuesday, February 16 at 2:00pm CET Regulatory News: Sensorion (Paris:ALSEN)(FR0012596468 ALSEN) a pioneering clini...
Half-year report on the Sensorion liquidity contract with Kepler Cheuvreux Regulatory News: Sensorion (FR0012596468 ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, issued the half-year report on its liquidity contract with Kepler Chevreux. As of December 31, 2020, the following assets appeared on the liquidity account Sensorion ordinary shares 33 243,51 It is reminded that as of June 30, 2020, the following assets appeared on the liquidity...